China Resources Double Crane: Wholly-owned subsidiary Qinhuangdao Purple Bamboo Pharmaceutical Co., Ltd. passes GMP compliance inspection.

China Resources Shuanghe announced that its wholly-owned subsidiary, Qinhuangdao Zizhu Pharmaceutical Co., Ltd., has received the "Notice of Drug GMP Compliance Inspection for Estrogen Raw Materials" issued by the Hebei Provincial Drug Administration. This inspection is the first drug GMP compliance inspection before the listing of estrogen raw materials and did not involve any investment. Through this inspection, the company has demonstrated that its product production quality management meets GMP requirements, which is beneficial for maintaining stable product quality and sustainable production capacity. However, it will not have a significant impact on the company's performance. The sales of pharmaceutical products are influenced by factors such as policies and market environment, leading to uncertainty.